Description
Eli Lilly’s Growth Spurt: Will Harris’ Drug Pricing Agenda Bring It to a Halt?
Eli Lilly and Company reported a robust performance for the second quarter of 2024, demonstrating significant strides in revenue growth and pipeline development, which are integral to the company’s future trajectory. Notably, a 36% increase in revenue was driven primarily by the surging demand for new products like Mounjaro and Zepbound, enhanced access, and expanded supply capabilities.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
